Treatment and lifestyle profiles of healthy aging survivors: A report from the Childhood Cancer Survivor Study.

T Timothy James Daeeun Ohlsen (Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA) K Kerry Ye (St. Jude Children's Research Hospital, Memphis, TN) C Cindy Im R Rusha Bhandari (Department of Population Sciences, City of Hope, Duarte, CA) Y Yan Chen S Stephanie B. Dixon K Kirsten K. Ness L Lucie Marie Turcotte (University of Minnesota, Minneapolis, MN) Y Yutaka Yasui J Jennifer M. Yeh (Boston Children's Hospital and Harvard Medical School, Boston, MA) G Gregory T. Armstrong P Paul C. Nathan C Claire Frances Snyder (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD) K Kevin C. Oeffinger (DCI Center for Onco‐Primary Care Duke University Durham North Carolina USA) E Eric Jessen Chow (Fred Hutch Cancer Center, Seattle, WA)

Abstract

10058 Background: Survivors of childhood cancer are at elevated risk for adverse health outcomes, but many maintain excellent health throughout adulthood. We sought to characterize the trajectories of, and examine factors associated with, healthy aging across the lifespan. Methods: We longitudinally surveyed ≥5 y cancer survivors (18-64 y) and sibling controls enrolled in the Childhood Cancer Survivor Study. “Healthy aging” was defined by 1) having a cumulative number of severe or life-threatening (i.e., grade 3+) chronic health conditions (CHCs) less than or equal to the mean of same age, same sex sibling controls; and 2) having no functional impairment or activity limitations. We then examined prevalences of healthy aging and its 2 component domains across survivor age groups ( < 30, 30-39, 40-49, ≥50 y). Multivariable logistic regression models adjusted for demographic, treatment, and lifestyle factors at cohort entry estimated risk factors for healthy aging among survivors. Results: We analyzed 17,263 survivors (median age 39 y, IQR 32-46) and 3,378 siblings. Among all sibling age/sex groups, mean grade 3+ CHC counts were < 1. Of survivors, 53.4% (95% CI 52.7-54.2) had no Grade 3+ CHC, and 71.4% (95% CI 70.7-72.1) reported no functional impairment. Overall, 45.0% (95% CI 44.2-45.7) of survivors met criteria for healthy aging, but this prevalence decreased with age (Table). In multivariable analysis, treatment factors associated with lower odds of healthy aging included anthracycline dose (≥250 mg/m 2 vs none: OR 0.60, 95% CI 0.52-0.69), alkylator dose (≥8 g/m 2 vs none: OR 0.76, 95% CI 0.67-0.86), and stem cell transplant (OR 0.60, 95% CI 0.41-0.89). High doses of radiation to any site were also associated with less healthy aging (e.g., ≥30 Gy to brain vs none: OR 0.22, 95% CI 0.19-0.26). Baseline physical activity > 180 min/week was associated with healthy aging (vs < 180 min: OR 1.23, 95% CI 1.11-1.37). Underweight, overweight, and obese baseline BMIs had lower odds of healthy aging compared with normal BMI (ORs 0.54 to 0.82, each p < 0.05). Survivors treated in more recent decades were more likely to experience healthy aging (1990s vs 1970s: OR 1.26, 95% CI 1.06-1.50) even after adjusting for attained age. Conclusions: Among childhood cancer survivors, the prevalence of healthy aging declines with age but has improved in more recent treatment eras. Higher levels of exercise and normal BMI at baseline were associated with subsequent healthy aging, suggesting that the trajectory of aging could be improved through targeted interventions. Prevalence (%) of outcomes across survivor age groups (95% CI). <30 y 30-39 y 40-49 y ≥50 y CHC count ≤ sibling mean for age/sex 67.4 (65.8, 69.0) 59.3 (58.1, 60.5) 47.5 (46.2-48.9) 34.4 (32.6-36.2) No functional impairment 76.0 (74.6, 77.5) 73.9 (72.8, 74.9) 69.4 (68.2-70.7) 64.1 (62.3-65.9) Healthy aging 58.0 (56.3, 59.7) 50.8 (49.5, 52.0) 39.2 (37.8-40.5) 27.2 (25.5-28.9)

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 10058-10058
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (15)

T

Timothy James Daeeun Ohlsen

Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA

K

Kerry Ye

St. Jude Children's Research Hospital, Memphis, TN

C

Cindy Im

R

Rusha Bhandari

Department of Population Sciences, City of Hope, Duarte, CA

Y

Yan Chen

S

Stephanie B. Dixon

K

Kirsten K. Ness

L

Lucie Marie Turcotte

University of Minnesota, Minneapolis, MN

Y

Yutaka Yasui

J

Jennifer M. Yeh

Boston Children's Hospital and Harvard Medical School, Boston, MA

G

Gregory T. Armstrong

P

Paul C. Nathan

C

Claire Frances Snyder

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD

K

Kevin C. Oeffinger

DCI Center for Onco‐Primary Care Duke University Durham North Carolina USA

E

Eric Jessen Chow

Fred Hutch Cancer Center, Seattle, WA